Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease

Geriatrics and Gerontology International

Volumn 12, Issue 2, 2012, Pages 207-214

  Kume, Kazumasa ^a   Hanyu, Haruo ^a   Sakurai, Hirofumi ^a   Takada, Yusuke ^a   Onuma, Takeshi ^a   Iwamoto, Toshihiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Amlodipine; Cerebral blood flow; Cognition; Hypertension; Telmisartan

Indexed keywords

AMLODIPINE; DONEPEZIL; IOFETAMINE I 123; TELMISARTAN;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; BRAIN BLOOD FLOW; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITION; CONTROLLED STUDY; CUNEUS; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LINGUAL GYRUS; MALE; MINI MENTAL STATE EXAMINATION; OCCIPITAL GYRUS; PARAHIPPOCAMPAL GYRUS; PARIETAL LOBE; POSTERIOR CINGULATE; PRIORITY JOURNAL; REGIONAL CEREBRAL BLOOD FLOW; SUPRAMARGINAL GYRUS; SYSTOLIC BLOOD PRESSURE; TEMPORAL LOBE; WECHSLER MEMORY SCALE;

AGED; ALZHEIMER DISEASE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BRAIN; CEREBROVASCULAR CIRCULATION; COGNITION; FEMALE; HUMANS; HYPERTENSION; MALE; PROSPECTIVE STUDIES; REGIONAL BLOOD FLOW; SINGLE-BLIND METHOD;

EID: 84859006978     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2011.00746.x     Document Type: Article

References (42)

1. Launer L, Masaki K, Petrovitch H etal. The association between midlife blood pressure levels and late-life cognitive function. JAMA 1995; 274: 1846-1851.
2. Skoog I, Lernfelt B, Landahl S etal. A 15year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145.
3. Kilander L, Nyman H, Boberg M etal. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998; 31: 780-786.
4. Mielke MM, Rosenberg PB, Tschanz J etal. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007; 69: 1850-1858.
5. Roselli F, Tartaglione B, Federico F etal. Rate of MMSE score change in Alzheimer's disease: influence of education and vascular risk factors. Clin Neurol Neurosurg 2009; 111: 327-330.
6. Regan C, Katona C, Walker Z etal. Relationship of vascular risk to the progression of Alzheimer disease. Neurology 2006; 67: 1357-1362.
7. Forette F, Seux ML, Staessen JA etal. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046-2052.
8. Ohrui T, Matsui T, Yamaya M etal. Angiotensin-converting enzyme inhibitiors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 2004; 52: 649-650.
9. Sink KM, Leng X, Williamson J etal. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension. Results from the Cardiovascular Health Study. Arch Intern Med 2009; 159: 1195-1202.
10. Li N-C, Lee A, Whitmer RA etal. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
11. Benson SC, Pershadsingh HA, Ho CI etal. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
12. Landreth G. Therapeutic use of agonists of the nuclear receptor PPARγ in Alzheimer's disease. Curr Alzheimer Res 2007; 4: 159-164.
13. Neumann KF, Rojo L, Navarrete LP etal. Insulin resistance and Alzheimer's disease: molecular links & Clinical implications. Curr Alzheimer Res 2008; 5: 438-447.
14. Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator-activated receptor-γ (PPARγ) in Alzheimer's disease. CNS Drugs 2008; 22: 1-14.
15. Watson GS, Cholerton BA, Reger MA etal. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone. A preliminary study. Am J Geriatr Psychiatry 2005; 13: 950-958.
16. Risner ME, Saunders AM, Altman JFB etal. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenom J 2006; 6: 246-254.
17. Sato T, Hanyu H, Hirao K etal. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011 32: 1626-33
18. Hanyu H, Hirao K, Shimizu S etal. Favourable effects of nilvadipine on cognitive function and regional cerebral blood flow on SPECT in hypertensive patients with mild cognitive impairment. Nucl Med Commun 2007; 28: 281-287.
19. Hughes CP, Berg L, Danziger WL etal. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-572.
20. McKhann G, Drachman D, Folstein M etal. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
21. Sheikh JI, Yesavage JA. Geriatric depression scale (GDS), recent evidence and development of a shorter version. Clin Gerontol 1986; 5: 165-173.
22. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
23. Honma A, Fukuzawa K, Tsukada Y etal. Development of a Japanese version of Alzheimer's disease Assessment Scale (ADAS). Jpn J Geriatr Psychiatry 1992; 3: 647-655.
24. Wechsler D. The Wechsler Memory Scale-Revised: Manual. San Antonio, TX: The Psychological Corporation, 1987.
25. Minoshima S, Frey KA, Koeppe RA etal. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36: 1238-1248.
26. Talairach J, Tournoux P. Co-Planar Stereotactic Atlas of the Human Brain. New York: Thieme, 1998.
27. Mizumura S, Kumita S, Cho K etal. Development of quantitative analysis method for stereotactic brain image: assessment of reduced accumulation in extent and severity using anatomical segmentation. Ann Nucl Med 2003; 17: 289-295.
28. Rockwood K, Fay S, Gorman M. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. Int J Geriatr Psychiatry 2010; 25: 191-201.
29. Kehoe PG, Wilcock GK. Is inhibition of the rennin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007; 6: 373-378.
30. Saxby BK, Harrington F, Wesnes KA etal. Candesartan and cognitive decline in older patients with hypertension. A study of the SCOPE trial. Neurology 2008; 70: 1858-1866.
31. Wang J, Ho L, Chen L etal. Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117: 3393-3402.
32. Tsukuda K, Mogi M, Iwanami J etal. Cognitive deficit in amyloid-β-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation. Hypertension 2009; 54: 782-787.
33. Washida K, Ihara M, Nishio K etal. Nonhypotensive dose of telmisartan attenuates cognitive impairment partly due to peroxisome proliferator-activated receptor-γ activation in mice with chronic cerebral hypoperfusion. Stroke 2010; 41: 1798-1806.
34. Mogi M, Li J-M, Iwanami J etal. Telmisartan prevented cognitive decline partly due to PPRA-γ activation. Biophys Res Commun 2008; 375: 446-449.
35. Combs CK, Johnson DE, Karlo JC etal. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000; 20: 558-567.
36. Sastre M, Dewachter I, Rossner S etal. Nonsteroidal anti-inflammatory drugs repress beta- secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 2006; 103: 443-448.
37. Heneka MT, Sastre M, Dumitrescu-Ozimek L etal. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain 2005; 128: 1442-1453.
38. Camacho IE, Serneels L, Spittaels K etal. Peroxisome proliferator-activated receptor γ induces a clearance mechanism for the amyloid-β peptide. J Neurosci 2004; 24: 10908-10917.
39. d'Abramo C, Ricciarelli R, Pronzato MA, Davis P. Troglitazone, a peroxisome proliferator-activated receptor-c agonist, decreases tau phosphorylation in CHOtau4R cells. J Neurochem 2006; 98: 1068-1077.
40. Haxby JV, Raffaele K, Gillette J etal. Individual trajectories of cognitive decline in patients with dementia of the Alzheimer type. J Clin Exp Neuropsychol 1992; 14: 575-592.
41. Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 2004; 12: 554-570.
42. Ishii K, Willoch F, Minoshima S etal. Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med 2001; 42: 548-557.